Tag: source

TORONTO, July 11, 2025 (GLOBE NEWSWIRE) -- Rogers Communications, Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) today announced the commencement of separate offers (the “Offers”) to purchase for cash any and all of the outstanding notes of each series listed in the table below (collectively, the “Notes”), up to a maximum of US$1,250,000,000 aggregate Total Consideration (as defined below). Subject to the Consideration Cap Condition (as defined below), the series of Notes that are purchased in the Offers will be based on the acceptance priority levels (each, an “Acceptance Priority Level”) set forth in the table below. If a given series of Notes is accepted for purchase pursuant to the Offers, all Notes of that series that are validly tendered and not validly withdrawn will be accepted for purchase. No series of Notes will be subject to proration pursuant to the Offers.

TORONTO, July 11, 2025 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (“Rogers” or the “Company”) (TSX: RCI.A and RCI.B; NYSE: RCI) today announced the commencement of separate offers (the “Offers”) to purchase for cash up to C$400,000,000 (the “Maximum Purchase Amount”) in aggregate purchase price, excluding accrued and unpaid interest, of its outstanding senior notes of each series listed in the table below (collectively, the “Notes”), which Maximum Purchase Amount may be increased, decreased or waived by the Company in its sole discretion. Each Offer is subject to the satisfaction or waiver of certain conditions.

New on-premises grammar engine to revolutionize enterprise language accuracy using proprietary data

Exhale Wellnes was recently ranked No.1 THCA flower brand by industry peers. Read more about its product line, bestsellers, and why it stood out. 

PHILADELPHIA and VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI).

SINGAPORE, July 11, 2025 (GLOBE NEWSWIRE) -- DexLab, the leading Solana-native token launching & tooling platform, today announced the launch of its fully independent Asia-Pacific subsidiary CaLab. Built on DexLab's battle-tested technical infrastructure, CaLab will operate as a regional powerhouse focused on serving APAC markets while maintaining technological interoperability with its parent platform.